Assessment of Risk of Bias in Osteosarcoma and Ewing's Sarcoma Randomized Controlled Trials: A Systematic Review

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2021 Oct 22

PMID 34677240

Citations 4

Authors

Robert Koucheki

Aaron M Gazendam

Jonathan R Perera

Anthony Griffin

Peter Ferguson

Jay Wunder

Kim Tsoi

Affiliations

Soon will be listed here.

Abstract

Aim: The aim of this study was to systematically assess the risk of bias in osteosarcoma and Ewing's sarcoma (ES) randomized controlled trials (RCT) and to examine the relationships between bias and conflict of interest/industry sponsorship.

Methods: An OVID-MEDLINE search was performed (1976-2019). Using the Cochrane Collaboration guidelines, two reviewers independently assessed the prevalence of risk of bias in different RCT design domains. The relationship between conflicts of interest and industry funding with the frequency of bias was examined.

Results: 73 RCTs met inclusion criteria. Prevalence of low-risk bias domains was 47.3%, unclear-risk domains 47.8%, and 4.9% of the domains had a high-risk of bias. Domains with the highest risk of bias were blinding of participants/personnel and outcome assessors, followed by randomization and allocation concealment. Overtime, frequency of unclear-risk of bias domains decreased (χ = 5.32, = 0.02), whilst low and high-risk domains increased (χ = 8.13, = 0.004). Studies with conflicts of interest and industry sponsorships were 4.2 and 3.1 times more likely to have design domains with a high-risk of bias ( < 0.05).

Conclusion: This study demonstrates that sources of potential bias are prevalent in both osteosarcoma and ES RCTs. Studies with financial conflicts of interest and industry sponsors were significantly more likely to have domains with a high-risk of bias. Improvements in reporting and adherence to proper methodology will reduce the risk of bias and improve the validity of the results of RCTs in osteosarcoma and ES.

Citing Articles

Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review.

Madi K, Flumian C, Olivier P, Sommet A, Montastruc F BMJ Med. 2023; 2(1):e000352.

PMID: 37779893 PMC: 10537984. DOI: 10.1136/bmjmed-2022-000352.

B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma.

Bottino C, Vitale C, Dondero A, Castriconi R Cancers (Basel). 2023; 15(13).

PMID: 37444389 PMC: 10340324. DOI: 10.3390/cancers15133279.

Scoping Review of Published Oncology Meta-analyses in High-Impact Oncology Journals.

Haslam A, Tuia J, Prasad V JAMA Netw Open. 2023; 6(6):e2318877.

PMID: 37358855 PMC: 10293908. DOI: 10.1001/jamanetworkopen.2023.18877.

Ultrasound-guided erector spinae plane block for postoperative analgesia in Chinese patients undergoing laparoscopic cholecystectomy: a double-blind randomized controlled trial.

Lu H, Xie Q, Ye W, Zhou Z, Lei Z Langenbecks Arch Surg. 2023; 408(1):111.

PMID: 36854802 DOI: 10.1007/s00423-023-02834-3.

References

Tsunemoto H, Arai T, Morita S, Ishikawa T, Aoki Y, Takada N . Japanese experience with clinical trials of fast neutrons. Int J Radiat Oncol Biol Phys. 1982; 8(12):2169-72. DOI: 10.1016/0360-3016(82)90564-8. View

Joksimovic L, Koucheki R, Popovic M, Ahmed Y, Schlenker M, Ahmed I . Risk of bias assessment of randomised controlled trials in high-impact ophthalmology journals and general medical journals: a systematic review. Br J Ophthalmol. 2017; 101(10):1309-1314. DOI: 10.1136/bjophthalmol-2017-310313. View

Paulussen M, Craft A, Lewis I, Hackshaw A, Douglas C, Dunst J . Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008; 26(27):4385-93. DOI: 10.1200/JCO.2008.16.5720. View

Meyers P, Schwartz C, Krailo M, Healey J, Bernstein M, Betcher D . Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008; 26(4):633-8. DOI: 10.1200/JCO.2008.14.0095. View

Bhandari M, Busse J, Jackowski D, Montori V, Schunemann H, Sprague S . Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ. 2004; 170(4):477-80. PMC: 332713. View

Gallegos-Castorena S, Martinez-Avalos A, Mohar-Betancourt A, Guerrero-Avendano G, Zapata-Tarres M, Medina-Sanson A . Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatr Hematol Oncol. 2007; 24(6):403-8. DOI: 10.1080/08880010701451244. View

SINGER J, Hartley J, Brennan C, Nicholson P, Souhami R . The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study. Br J Cancer. 1998; 77(6):978-84. PMC: 2150089. DOI: 10.1038/bjc.1998.161. View

Zhang S, Li X, Li H, Sun X, Yan X . Significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on GLS1 expression. Eur Rev Med Pharmacol Sci. 2018; 22(19):6538-6544. DOI: 10.26355/eurrev_201810_16068. View

. A trial of chemotherapy in patients with osteosarcoma (a report to the Medical Research Council by their Working Party on Bone Sarcoma. Br J Cancer. 1986; 53(4):513-8. PMC: 2001430. DOI: 10.1038/bjc.1986.81. View

10.

IVINS J, RITTS R, Pritchard D, Gilchrist G, Miller G, Taylor W . Transfer factor versus combination chemotherapy: a preliminary report of a randomized postsurgical adjuvant treatment study in osteogenic sarcoma. Ann N Y Acad Sci. 1976; 277(00):558-74. DOI: 10.1111/j.1749-6632.1976.tb41730.x. View

11.

Min Y, Kim S, Suh C, Park J, Kim H, Kim J . The possible cost effectiveness of peripheral blood stem cell mobilization with cyclophosphamide and the late addition of G-CSF. J Korean Med Sci. 2000; 15(1):49-52. PMC: 3054601. DOI: 10.3346/jkms.2000.15.1.49. View

12.

Beyari M, Hak A, Li C, Lamfon H . Conflict of interest reporting in dentistry randomized controlled trials: a systematic review. J Evid Based Dent Pract. 2014; 14(4):158-64. DOI: 10.1016/j.jebdp.2014.06.002. View

13.

Gazendam A, Bozzo A, Schneider P, Giglio V, Wilson D, Ghert M . Recruitment patterns in a large international randomized controlled trial of perioperative care in cancer patients. Trials. 2021; 22(1):219. PMC: 7981833. DOI: 10.1186/s13063-021-05149-0. View

14.

Malek F, Somerson J, Mitchel S, Williams R . Does limb-salvage surgery offer patients better quality of life and functional capacity than amputation?. Clin Orthop Relat Res. 2012; 470(7):2000-6. PMC: 3369104. DOI: 10.1007/s11999-012-2271-1. View

15.

Dunst J, Jurgens H, Sauer R, Pape H, Paulussen M, Winkelmann W . Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol Biol Phys. 1995; 32(4):919-30. DOI: 10.1016/0360-3016(95)00016-r. View

16.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

17.

Probst P, Zaschke S, Heger P, Harnoss J, Huttner F, Mihaljevic A . Evidence-based recommendations for blinding in surgical trials. Langenbecks Arch Surg. 2019; 404(3):273-284. DOI: 10.1007/s00423-019-01761-6. View

18.

Chess L, Gagnier J . Risk of bias of randomized controlled trials published in orthopaedic journals. BMC Med Res Methodol. 2013; 13:76. PMC: 3724580. DOI: 10.1186/1471-2288-13-76. View

19.

Gherlinzoni F, Picci P, Bacci G, Campanacci D . Limb sparing versus amputation in osteosarcoma. Correlation between local control, surgical margins and tumor necrosis: Istituto Rizzoli experience. Ann Oncol. 1992; 3 Suppl 2:S23-7. DOI: 10.1093/annonc/3.suppl_2.s23. View

20.

Shamberger R, LaQuaglia M, Krailo M, Miser J, Pritchard D, Gebhardt M . Ewing sarcoma of the rib: results of an intergroup study with analysis of outcome by timing of resection. J Thorac Cardiovasc Surg. 2000; 119(6):1154-61. DOI: 10.1067/mtc.2000.106330. View